VEGFR

VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. Also, they may be membrane-bound (mbVEGFR) or soluble (sVEGFR), depending on alternative splicing.

Cat. No.	Product name	CAS No.	Purity
T6289	Dovitinib	405169-16-6	99.78%
T6289	Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) an...
T2500	Cediranib	288383-20-0	99.78%
T2500	Cediranib (AZD2171) (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (I...
TQ0041	Ningetinib Tosylate	1394820-77-9	99.77%
TQ0041	Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
TQ0021	Ningetinib	1394820-69-9	99.77%
TQ0021	Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
T2624	OSI-930	728033-96-3	99.76%
T2624	OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
T2288L	Motesanib Diphosphate	857876-30-3	99.76%
T2288L	Motesanib Diphosphate (AMG 706) is the orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activi...
T16549	PKI-166	187724-61-4	99.76%
T16549	PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastas...
TJS0339	Coumarin-3-carboxylic acid	531-81-7	99.76%
TJS0339	The combination of Valproic acid with Coumarin-3-carboxylic acid (3-Carboxycoumarin) suppresses the proliferation and migration of lung cancer cells via EGFR/VEG...
T4349	Sitravatinib	1123837-84-2	99.74%
T4349	Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
T2372	Ponatinib	943319-70-8	99.74%
T2372	Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively)...
T2446	KI8751	228559-41-9	99.73%
T2446	KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
T8482	Ripretinib	1442472-39-0	99.72%
T8482	Ripretinib (DCC-2618) is an orally bioavailable inhibitor of KIT and PDGFRA.
T17280	(Z)-Guggulsterone	39025-23-5	99.72%
T17280	(Z)-Guggulsterone inhibits the growth of human prostate cancer cells by causing apoptosis. Z-guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–...
T7945	SU14813	627908-92-3	99.72%
T7945	SU14813 is a multi-receptor tyrosine kinase inhibitor with potent antiangiogenesis and antitumor activity (IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ an...
T8326	BMS-2	888719-03-7	99.7%
T8326	BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
T3113	Foretinib	849217-64-7	99.7%
T3113	Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
T6930	Pazopanib Hydrochloride	635702-64-6	99.69%
T6930	Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM...
T3566	SU5205	3476-86-6	99.68%
T3566	SU5205 is a VEGFR2 inhibitor.
T6012	SAR131675	1433953-83-3	99.68%
T6012	SAR131675 is a potent and selective VEGFR3 inhibitor with an IC50 of 23 nM.
TN1557	Decursinol angelate	130848-06-5	99.65%
TN1557	Decursinol angelate has anti-tumor, anti-inflammatory, anti-oxidant, and hepatoprotective activities, it inhibits VEGF-induced angiogenesis via suppression of th...